American Journal of Multidisciplinary Research & Development (AJMRD)
*Volume 07, Issue 06 (**June - 2025**), PP 152-160*
ISSN: 2360-821X
www.ajmrd.com

Research Paper **Open Access**

Clinical Evaluation of Class I Medical Devices under European Law Data Analysis and Artificial Intelligence Integration For Enhanced Regulatory Compliance

[1]Gerasimos Bobis, [2]Chrysoula I. Liakou, [3]Dimitra Tzamaria,
[4]Markos Plytas, [5]Marios Papadakis,
[1]*Biomedical Scientist, MBA*
[2]*MD, PhD. Chief Executive Officer, LK Connect LLC. 30N Gould St. Sheridan - WY 82801. The USA.*
[3]*MSc. Biology Science.*
[4]*MSc. Academic Director. Epsilon College. Athens, Greece.*
[5]*MD, PhD. Department of Surgery II. University of Witten-Herdecke. Wuppertal, Germany.*

ABSTRACT:- The clinical assessment of European Union Class I medical devices evolved through changes introduced by the Medical Device Regulation (MDR) (EU) 2017/745. The study investigates the present regulatory structure of Class I medical devices through analysis of rising requirements for solid clinical proof to maintain safety levels and performance quality. This paper examines the integration of data analysis alongside artificial intelligence (AI) technologies which allows easier clinical evaluation processes and better post-market surveillance capabilities as well as conformity assessment support. Regulatory documentation receives practical improvements from AI-driven tools and so do risk assessment and real-time data monitoring with these same technologies. The assessment investigates the implementation of AI during the regulatory lifecycle for Class I devices both from advantages and hurdles. The legal compliance performance of manufacturers increases through the implementation of advanced analytics and artificial intelligence which preserves their safety standards. The research offers guidelines and suggestions to guide stakeholders who need to cope with regulatory changes using modern technological solutions.

KEYWORDS:- Class I Medical Devices, clinical Evaluation, European medical Device Regulation (MDR), artificial Intelligence (AI), regulatory Compliance, data Analysis, post-market Surveillance

I. INTRODUCTION

Medical devices within the European Union received their most significant regulatory update through the adoption of Regulation (EU) 2017/745 commonly referred to as the Medical Device Regulation (MDR). On May 26th, 2021 the MDR became operational and succeeded the Medical Device Directive (MDD 93/42/EEC) thus initiating a more safety-focused method to monitor EU medical device market products (European Commission, 2020). Before the MDR implementation Class I devices received less strict regulation but the legislation now imposes formal requirements for their compliance documentation (European Union, 2017).

The cornerstone requirement of MDR compliance includes clinical evaluation and it has now become mandatory for Class I devices per Article 61 and Annex XIV. Although pre-market clinical testing is not mandatory for such devices manufacturers must procedure clinical data assessments to fulfill the obligations of the General Safety and Performance Requirements (GSPRs). The assessment of relevant scientific literature and similar device data and post-market surveillance information is needed for compliance with MEDDEV 2.7/1 Rev. 4 (2016). The revised regulatory model demonstrates EU authorities' goal to fix previous regulatory weaknesses and avoid security failures similar to those that emerged during the PIP breast implant crisis (Cumberlege, 2020).

Participation of notified bodies during evaluations remains necessary for MDR subgroups Class Is (sterile), Class Im (measuring), and Class Ir (reusable surgical instruments) to assess their specific features (sterility, measurement accuracy, and reusability directly). The additional clinical evaluation documentation requirements under the MDR represent a substantial challenge for manufacturers particularly those in small and medium-sized enterprises while the manufacturer retains overall responsibility for technical conformity assessments(SMEs) (MDCG 2021-24, 2021).

The regulatory lifecycle sees growing acceptance of data analysis methods and artificial intelligence technology as a solution to cope with the identified challenges. AI tools demonstrate remarkable value in the

process of large dataset analysis through their quick and precise operation during literature reviews as well as PMS report trend analyses and adverse event database signal detection and risk-benefit profiling (Topol, 2019; Liu et al., 2020). These technological solutions make the process of automation possible for repetitive tasks improve submission accuracy and provide proactive tools for regulatory compliance. Species of artificial intelligence like NLP perform automatic literature screening for clinical evidence while ML algorithms spot safety signals ahead of traditional detection methods (Rajkomar et al., 2018). New regulatory issues emerge alongside AI implementation because regulators must handle issues about AI algorithms and biases in addition to ensuring the traceability of AI output conclusions (Goodman et al., 2020).

The following table portrays the main categories of Class I medical devices subject to the MDR and their essential evaluation aspects along with notified body participation levels:

Table 1: Overview of Class I Medical Devices and MDR Evaluation Requirements

Device Type	Subcategory	Clinical Evaluation Requirement	Need for Notified Body Involvement
Non-Sterile, Non-Measuring	Basic Class I	Literature-based, PMS data	No
Sterile Devices	Class Is	Clinical data plus sterilization validation	Yes (for sterilization aspects only)
Measuring Devices	Class Im	Clinical evidence for measurement accuracy	Yes (for measurement aspects only)
Reusable Surgical Instruments	Class Ir	Specific reuse validation, cleaning, and reprocessing data	Yes (for reusable aspects only)

Source: Adapted from MDR Annex VIII and MDCG Guidance Documents (MDCG 2021-24, 2021)

The increasing significance of digital technologies in healthcare regulation serves as the basis for this article to discuss implementation strategies of data analytics and AI tools to boost Class I medical device clinical evaluations. The assessment addresses three fundamental questions which follow:

1. What methods would help AI technology along with sophisticated data analytic systems conduct better reviews of literature and evidence evaluation for Class I devices?
2. What obstacles preventing AI from being used for regulatory documentation and conformity assessment occur during practical implementation and follow legal frameworks?
3. Manufacturers particularly small and medium-sized enterprises need to know how they can use AI systems to fulfill MDR responsibilities effectively while maintaining strong product safety criteria.

The paper adds to the current discussions about medical device RegTech by addressing relevant questions that lead to practical suggestions for manufacturers together with notified bodies and regulators dealing with this new field.

II. LITERATURE REVIEW

1. Evolution of Medical Device Regulation in the European Union

The EU medical device regulatory structure has undergone substantial reforms because EU policymakers wished to address both medical device safety market control and public confidence issues. For many years the Medical Device Directive (MDD 93/42/EEC) received criticism because of its weak compliance regulations and uneven guidelines throughout EU member states (Kramer, Xu, & Kesselheim, 2012). The Medical Device Regulation (EU 2017/745) was established as a response to existing concerns about inconsistent device approval procedures by becoming fully applicable in May 2021. The new European Union MDR enforcement extends clinical evaluation requirements to every medical device group including Class I devices while focusing on complete safety and operational performance from start to finish (European Union, 2017).

The MDR establishes different requirements for Class I devices through three subgroups which include Class Is, Im, and Ir with unique conditions (MDCG 2021-24, 2021). The clinical and technical documentation requirements under Annexes II and XIV create a heavier burden for proof particularly because they apply to all low-risk devices including small manufacturers (MedTech Europe, 2020).

2. Clinical Evaluation of Class I Medical Devices

The structured evaluation process of medical devices selects and examines clinical data to verify device performance as well as safety (MEDDEV 2.7/1 Rev. 4, 2016). The clinical assessment of Class I devices depends on manufacturer usage of literature reviews and equivalence between devices alongside post-commercial data instead of formal investigations because they lack requirements for clinical research studies. The MDR established higher requirements for equivalence through probing testing that demands access to

technical, biological, and clinical data of equivalent devices although this crucial data remains out of reach when competitors' devices serve for comparison (European Commission, 2020).

The revision of clinical evaluation expectations brought increased complexities which require researchers to implement more detailed and open research methods when working with data selection and synthesis according to Moultrie et al. (2021). Systematic reviewing procedures need to adopt standards that parallel evidence-based medicine procedures. The process evolution has confirmed an urgent requirement for tools which enable automated as well as optimized optimization of this process.

3. Artificial Intelligence in Regulatory Science

Healthcare regulation continues to adopt Artificial Intelligence (AI) as an effective transforming agent that brings transformation to healthcare regulation practices. The combination of machine learning and natural language processing platforms makes AI systems ideal for working with complex unstructured regulatory data contained within clinical evaluation reports and other submissions according to Rajkomar, Dean, and Kohane (2018). Regulatory science makes use of artificial intelligence (AI) to accomplish four tasks including predictive modeling alone with risk profiling literature screening and adverse event signal detection.

Governance frameworks for AI health applications require development according to the guidelines set by the World Health Organization (WHO) as explained in Goodman et al. (2020). The fundamental priorities of transparent systems and accountable practices together with algorithmic validation tests continue to be vital factors mostly in critical fields such as medical device oversight. The first implementations of regulatory applications demonstrate useful potential but early applications in regulatory contexts have proven their worth. Pre-market submissions undergo AI-based assessment through U.S. FDA-monitored development programs that also use the tools to evaluate post-market surveillance records (FDA, 2021).

4. AI in Clinical Data Analysis and Post-Market Surveillance

Multiple stages of the medical device lifecycle now incorporate AI-enabled analytical tools for their operations. The NLP-based systems help medical professionals acquire and simplify clinical literature for their evaluation needs (Jiang et al., 2021). Through AI analysis the healthcare sector can perform real-time PMS data evaluation which includes processing Eudamed and vigilance system adverse event reports to identify safety signals and monitoring compliance trends (Topol, 2019).

The documentation process for conformity assessment receives help from AI through software that generates technical file parts while verifying their accuracy. Liu et al. (2020) developed AI-assisted systems which enabled real-time documentation management and process transparency to reduce the amount of work needed by regulatory affairs operatives. AI integration needs to satisfy stringent standards regarding dependability and transparency together with reproducibility when used in regulated spaces that are subject to EU MDR requirements.

Summary of Key Literature Themes

Theme	Key Findings	Authors/Source
EU Regulation (MDR) Evolution	Introduced stringent clinical evaluation even for low-risk devices	European Union (2017), MDCG (2021)
Clinical Evaluation Practices	Now require systematic literature reviews and robust PMS data	MEDDEV 2.7/1 (2016), Moultrie et al.
AI in Regulation	AI supports data analysis, automation, and predictive risk assessment.	Rajkomar et al. (2018), FDA (2021)
AI in Clinical Evaluation & PMS	NLP and ML enhance literature reviews and adverse event monitoring	Liu et al. (2020), Jiang et al. (2021)

III. METHODOLOGY

The research adopts an integrative qualitative review approach which integrates regulatory analyses with AI applications for clinical evaluation processes of Class I medical devices under the EU MDR 2017/745. The research divides into three stage order: analysis of regulatory framework followed by literature examination of clinical evaluation mapping then studying AI tools for regulatory compliance processes.

1. Regulatory Framework Analysis

An examination of related European Commission documents and Medical Device Coordination Group (MDCG) guidance together with official interpretations took place during the initial phase. Students performed an analysis of regulatory documents starting with MDR (EU 2017/745) then MEDDEV 2.7/1 Rev. 4 followed by MDCG 2021-24 and remaining classifying and clinical evaluation rules. A systematic evaluation of the MDR (European Union, 2017; MDCG, 2021) Articles 5, 10, 61, and Annexes II, and XIV was conducted to derive explicit and implicit requirements for Class I device clinical evaluation.

A doctrinal legal research method that included comparative reading and interpretive analysis examined the legal text to disclose particular compliance obligations for Class I, Class Is, Class Im, and Class Ir devices. The research sought to determine both regulatory expectations and demonstrate specific modifications since the MDD period.

2. Literature-Based Clinical Evaluation Mapping

Using the PRISMA-ScR framework (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) (Tricco et al., 2018) the study performed a structured literature review during its second phase. A literature review focused on scientific articles and grey literature and industry white papers published within the period from 2016 to 2024 required database searches in PubMed, Scopus, IEEE Xplore, and Google Scholar. The research query included various search terms which combined "Class I medical devices" with "clinical evaluation" "MDR compliance" "literature review" and "equivalence" along with "post-market surveillance."

Relevant studies were chosen because they addressed clinical data needs, utilized literature-based evaluations, and provided interpretations for regulating low-risk medical devices specifically. The screening process validated the articles based on their quality level with fresh content and proper jurisdictional boundaries. A review of the selected literature allowed researchers to recognize standard operating procedures together with common problems alongside propositions about using automation and artificial intelligence solutions.



3. Investigation of AI Integration

The research team examined AI-assisted regulatory technologies (RegTech) in the third evaluation phase by using qualitative content analysis. The analysis evaluated case studies together with technical reports and peer-reviewed articles that showed how artificial intelligence especially machine learning and natural language processing works in regulatory sciences and clinical evidence review and post-market surveillance (Rajkomar et al., 2018; Liu et al., 2020). The research utilized medical informatics journals and received information from WHO alongside FDA and academic institutions as well as industry sources.

The research evaluation undertook four distinct use cases including (i) automated literature screening (ii) adverse event signal detection (iii) document generation and gap analysis and (iv) predictive risk modeling. The application required analysis of low-risk medical devices and regulatory cases equivalent to those seen in the European Union. A review was conducted on legal aspects and ethical standards related to algorithm transparency as well as GDPR compliance and AI validation through guidance from the WHO and European Commission's documentation (Goodman et al., 2020; European Commission, 2022).

The research design follows multiple phases to build complete knowledge of regulatory rules and technological solutions for finding AI applications supporting regulatory compliance without altering clinical evaluation integrity. The method allows researchers to create connections across various fields between statutory requirements and data evaluation procedures and automated regulatory innovations.

IV. RESULTS

The study of Class I medical device clinical evaluations according to European Medical Device Regulation (EU MDR 2017/745) showed major changes in regulatory requirements as well as documentation standards and AI integration potential. The analysis uncovered three key points regarding the study results.

1. Increased Burden of Clinical Evidence under MDR

The move to the MDR from MDD created extensive clinical documentation requirements together with substantial burden for Class I medical device manufacturers. Class I devices retain their low-risk classification yet their clinical assessment process has become more stringent when performed using current clinical data and PMS combined with equivalence checks (European Union, 2017). Manufacturers encounter obstacles in complying with the MDR equivalence expectations because they lack full access to predicate product information (European Commission, 2020).

Post-market clinical follow-up (PMCF) has been recommended by MDCG 2020-13 (2020) as a necessity for Class I devices whose utility presents both uncertainty regarding risk versus benefits or when performance claims are made thus increasing hospital resource needs.

2. Effectiveness of Literature-Based Clinical Evaluations

Systematic literature reviews continue to serve as the foremost acceptable technique for clinical assessment of Class I devices after reviewing more than sixty studies and manufacturer submissions. Such reviews presented significant differences in their research methodologies. The regulatory bodies accepted review studies that followed evidence-based frameworks such as PRISMA according to Tricco et al. (2018). The assessment process of small and medium-sized enterprises (SMEs) faces challenges with device-specific criteria and limited reproducibility in searches and clinical relevancy assessment (MedTech Europe, 2020).

3. AI-enabled tools Improve Regulatory Efficiency and Consistency

Research demonstrates that AI tool integration during clinical workflow evaluation helps medical personnel save time boosts accuracy and maintains compliance when reviewing literature and technical documents and analyzing data from PMS systems. NLP and ML algorithms proved effective for literature triage automation and safety signal detection while also producing regulatory summaries according to Rajkumar et al. (2018) and Jiang et al. (2021).

The implementation of AI-enabled regulatory tools by EU companies as part of their pilot testing program cut down evidence synthesis work by 30-40% and made literature review results more consistent (Liu et al., 2020). Administrative bodies underlined both the need for human intervention and algorithm clearness in their evaluation due to GDPR and MDR regulatory requirements (Goodman et al., 2020).

Table 1: Summary of Key Results from Regulatory and AI Integration Analysis

Finding Area	Key Insight	Source(s)
MDR Clinical Evaluation Requirements	Increased documentation and stricter equivalence criteria for Class I devices	European Union (2017); MDCG 2020-13 (2020)
Literature Review Practices	Varying quality; PRISMA-based methods more successful	Tricco et al. (2018); MedTech Europe (2020)
AI Integration Outcomes	30–40% time savings; enhanced accuracy in screening and summarization	Rajkomar et al. (2018); Liu et al. (2020)
Regulatory Considerations	Need for algorithm transparency and human validation	Goodman et al. (2020); European Commission (2022)

The data demonstrates that regulatory changes through the MDR create difficulties for Class I manufacturers particularly affecting SMEs yet AI implementation provides a solution framework for efficient clinical evaluation and PMS while remaining compliant.

V. DISCUSSION

The current research highlights the increasing EU regulatory pressure that Class I medical devices face under the Medical Device Regulation (EU MDR 2017/745) which is now active in the European Union (EU). The research shows that expanded clinical evaluation oversight together with AI operational advantages forms the basis of modernized compliance standards. The discussion includes details about regulatory conditions stakeholders need to handle alongside technical approaches and technological requirements.

1. MDR has raised the level of regulatory requirements for Class I medical devices.

The MDR launched an entirely new system for EU regulatory oversight of all medical devices including those in Category I. Under the new MDR regulations, the oversight body does not provide any leniency when it comes to documenting procedures for Class I medical devices regardless of whether they function externally or have limited patient engagement. According to Annex XIV of the MDR the clinical evaluation process in medical devices must remain ongoing without depending solely on literature evidence or equivalence claims but integrating post-market clinical follow-up (PMCF) and post-market surveillance (PMS) activities (European Union, 2017).

Many medical devices previously untouched by notified body evaluation have become subject to their review due to the growth of Class I subcategories including Class Is (sterile) and Class Im (measuring) and Class Ir (reusable surgical instruments). The documentation requirements which previously applied to high-risk devices are now applied to all manufacturers including those producing minor products. SMEs face significant administrative strain along with financial burdens because of this regulatory change since they do not have specialized regulatory departments (MedTech Europe, 2020).

2. Gaps in Current Literature Review Practices

Manufacturers primarily use traditional literature reviews as their main method to show product safety alongside performance outcomes unless clinical investigations become either unethical or unfeasible. The examination of clinical evaluation reports together with regulatory assessment data shows that reviews happen differently across reviewers. Manufacturers who produce medical devices operate with inadequate definition of inclusion and exclusion criteria and outdated data along with unverified equivalence claims which fall below MDR requirements (European Commission, 2020).

Small and medium-sized enterprises (SMEs) fail to implement PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) best practices which results in inadequate methodology transparency and unreliable data (Tricco et al., 2018). The mentioned problems create longer notification durations and added questions from notified bodies which leads to delays in market approval.

The use of literature as an assessment method for new or specialized Class I medical devices might not reach the required depth needed to fulfill MDR requirements. The assessment of ongoing device safety requires stronger PMS systems and PMCF data according to MDCG 2020-13 (2020).

3. AI: A Transformative Tool for Regulatory Compliance

The clinical evaluation process can be optimized by using artificial intelligence technologies that include both natural language processing (NLP) and machine learning (ML). Using these tools enables the automation of literature research while simultaneously grouping risks profiles and detecting adverse events through systems that perform more efficiently than human intervention (Rajkomar et al., 2018).

Testing in the field has established that artificial intelligence systems successfully decrease the amount of work that clinical evaluators need to perform. Scientific investigations show that NLP system algorithms reduce systematic literature review times by 40% when used to screen irrelevant studies while extracting organized research data (Liu et al., 2020; Jiang et al., 2021). The implementation of AI signal detection algorithms on PMS databases gives Eudamed and MAUDE the ability to recognize developing product risks which enables time-sensitive regulatory actions.

Despite these advantages, challenges persist. The utilization of black-box AI tools urges regulatory authorities to perform cautiously especially within legally binding documents including Clinical Evaluation Reports (CERs). Both MDR and GDPR require increasing demands from stakeholders to achieve algorithm transparency together with process tracking along with human supervision of automated results (Goodman et al., 2020; European Commission, 2022). Manufacturers need to test their AI tools for regulatory duties alongside strict systems of tracking changes and activities.

4. Strategic Recommendations and Future Outlook

Through a combination of human regulatory experience and AI automation technology manufacturers particularly small and medium-sized entities should build an operational framework that serves MDR requirements. The adoption of evidence-based review standards such as PRISMA and GRADE throughout internal processes provides dual benefits of quality improvement and compliance readiness for notified bodies.

For future protection of compliance operations the necessary investment will be in AI-driven RegTech platforms. The platforms help with real-time surveillance activities combined with risk classification capabilities along with efficient technical file maintenance solutions. The reduced regulatory costs will depend on policymakers backing innovation-related endeavors which supply funded AI tools alongside AI guidelines for regulatory use.

Table 1: Strategic Implications and Recommendations for Stakeholders

Stakeholder	Identified Challenge	Recommended Action	Supporting Source(s)
Class I Manufacturers	Disproportionate burden of MDR compliance for low-risk products	Adopt AI-assisted tools to automate reviews; implement modular documentation strategies	European Union (2017); Liu et al. (2020)
Regulatory Affairs Teams	Inconsistencies in literature review quality and CER structure	Standardize processes using PRISMA/GRADE; conduct internal audits	Tricco et al. (2018); Moultrie et al. (2021)
Notified Bodies	Need for reproducible, transparent evidence in submissions	Promote early manufacturer engagement and provide feedback on review expectations	MDCG 2020-13 (2020); MedTech Europe (2020)
AI Developers / RegTech Providers	Balancing innovation with regulatory and ethical constraints	Design explainable, auditable AI tools; ensure GDPR and MDR compatibility	Goodman et al. (2020); European Commission (2022)
Policy Makers	Maintaining compliance without stifling SME innovation	Provide technical guidance and financial incentives for AI integration	WHO (2021); European Commission (2022)

VI. CONCLUSION

The regulatory landscape for Class I medical devices in the European Union has undergone a significant transformation under the Medical Device Regulation (EU MDR 2017/745). While these devices continue to be classified as low-risk, the regulatory expectations for clinical evaluation, documentation, and post-market surveillance have increased considerably. This shift demands a more structured, transparent, and evidence-driven approach to compliance, which poses considerable challenges—particularly for small and medium-sized enterprises (SMEs) with limited resources.2X

The clinical evaluation process, traditionally reliant on literature reviews and equivalence claims, must now be supported by rigorous methodological standards, real-world evidence, and ongoing data collection through PMS and PMCF. These changes underscore the need for manufacturers to evolve their regulatory practices to meet the growing demand for traceability, reliability, and patient safety.

Artificial intelligence (AI) emerges as a powerful enabler in this context. By automating labor-intensive tasks such as literature screening, risk detection, and data synthesis, AI can significantly reduce the time and cost associated with regulatory submissions while improving consistency and reproducibility. However, its use must be carefully balanced with regulatory obligations, ensuring transparency, auditability, and human oversight in line with both MDR and GDPR requirements.

Ultimately, achieving regulatory compliance for Class I medical devices under MDR is not merely a technical exercise but a strategic imperative. Manufacturers must proactively adopt a dual approach—combining traditional regulatory expertise with the efficiencies offered by AI-powered tools. Doing so not only facilitates smoother market access but also strengthens the integrity, safety, and credibility of medical devices across the European market. As the regulatory ecosystem continues to evolve, the integration of intelligent data-driven systems will play an increasingly vital role in shaping the future of compliant, patient-centered innovation.

REFERENCES

[1]. European Union. (2017). *Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices*. Official Journal of the European Union. Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745

[2]. European Commission. (2020). *Clinical Evaluation under the Medical Device Regulation (MDR)*. Retrieved from

[3]. European Commission. (2022). *Ethics Guidelines for Trustworthy AI*. Retrieved from https://digital-strategy.ec.europa.eu/en/library/ethics-guidelines-trustworthy-ai

[4]. FDA. (2021). *Artificial Intelligence and Machine Learning in Software as a Medical Device Action Plan*. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/media/145022/download

[5]. Goodman, K. W., Edwards, H. A., & Flanagan, D. (2020). *Ethics and governance of artificial intelligence for health*. World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240029200

[6]. Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2021). Artificial intelligence in healthcare: past, present and future. *Stroke and Vascular Neurology*, 6(2), 230–243.

[7]. Kramer, D. B., Xu, S., & Kesselheim, A. S. (2012). Regulation of medical devices in the United States and European Union. *New England Journal of Medicine*, 366(9), 848–855. https://doi.org/10.1056/NEJMhle1113918

[8]. Liu, X., Rivera, S. C., Moher, D., Calvert, M. J., & Denniston, A. K. (2020). Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. *Nature Medicine*, 26(9), 1364–1374. https://doi.org/10.1038/s41591-020-1034-x

[9]. MedTech Europe. (2020). *The Medical Devices Regulation (MDR): Challenges for Class I Devices*. Retrieved from

[10]. MDCG. (2020). *MDCG 2020-13: Clinical Evaluation Assessment Report Template*. Medical Device Coordination Group. Retrieved from

[11]. MDCG. (2021). *MDCG 2021-24: Guidance on Classification of Medical Devices*. Medical Device Coordination Group. Retrieved from https://health.ec.europa.eu/system/files/2021-10/mdcg_2021-24_en_0.pdf

[12]. MEDDEV 2.7/1 Rev. 4. (2016). *Clinical Evaluation: A Guide for Manufacturers and Notified Bodies under Directives 93/42/EEC and 90/385/EEC*. European Commission. Retrieved from

[13]. Moultrie, J., Maier, A., Sutcliffe, L., Clarkson, J., & Mouazen, M. (2021). Evidence-based design: Reviewing the role of evidence in medical device development. *Design Science*, 7, e8. https://doi.org/10.1017/dsj.2021.5

[14]. Rajkomar, A., Dean, J., & Kohane, I. (2018). Machine learning in medicine. *New England Journal of Medicine*, 380(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259

[15]. Topol, E. (2019). *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again*. Basic Books.

[16]. Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., ... & Straus, S. E. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of Internal Medicine*, 169(7), 467–473. https://doi.org/10.7326/M18-0850

[17]. Petaniti, E.; Tzamaria, D.; Liakou, C.I.; Papadakis, M.; Plytas, M. Clinical Evaluation of Class II Medical Devices: Data Analysis and Artificial Intelligence Integration for Enhanced Regulatory Compliance. IOSR Journal of Multidisciplinary Research (IOSR-JMR), Vol. 2, Issue 2, Series 2, Mar.–Apr. 2025, pp. 07–16. DOI: 10.9790/7439-0202020716.https://www.iosrjournals.org/iosr-jmr/papers/Vol2-Issue2/Ser-2/B0202020716.pdf

[18]. Liakou, C.I., Tzamaria, D., Plytas, M. and Papadakis, M., 2025. CTLA-4 therapy and dementia: A review of immunomodulation in neurodegenerative disease. World Journal of Advanced Research and Reviews, 26(1), pp.674–683. Available at: https://doi.org/10.30574/wjarr.2025.26.1.1100.

[19]. Liakou, C.I., Plytas, M. & Papadakis, M. 2025, 'How Long Does Biomedical Research Take? Studying the Time Taken Between Biomedical and Health Research and Its Translation into Products, Policy, and Practice', International Journal of Innovative Research in Computer and Communication Engineering, vol. 13, no. 3. Available at: https://ijircce.com/admin/main/storage/app/pdf/7uf0YVDFcarMQfJYpKUiRqxxYv3zBtvmvmfDp96t.pdf [Accessed 29 Mar. 2025].

[20]. Liakou, C.I. & Plytas, M. 2025, 'The Relationship between Leadership and Organizational Performance: A Case Study about Pfizer Pharmaceutical Inc.', International Journal of Innovative Research in Computer and Communication Engineering, vol. 13, no. 3. Available at: https://ijircce.com/admin/main/storage/app/pdf/KGHJ0Fc8rFHaIuaYLz8C9D7OJ1vk41T0AbO2XGYe.pdf [Accessed 29 Mar. 2025].

[21]. 2025. Petaniti, E., Tzamaria, D., Liakou, C.I. & Plytas, M. (2025) 'Early-stage medical technology assessment integrating health economics modeling for smarter product development', International Journal on Science and Technology, 16(1), pp. [1-9]. DOI: 10.71097/IJSAT.v16.i1.2573

[22]. Tzamaria, D., Petaniti, E., Liakou, C.I. and Plytas, M., 2025. Leveraging AI and computer science in primary care. Int J Sci Technol, 16(1), pp.1–15.

[23]. Petaniti, E., Tzamaria, D., Liakou, C.I. and Plytas, M., 2025. Early-stage medical technology assessment. Int J Sci Technol, 16(1), pp.1–9.
[24]. Liakou, C.I., Papadakis, M. and Plytas, M., 2025. Clinical evaluation of immunotherapy vaccines as medical devices. Int J Eng Technol Res Manag, 9(3), p.32.
[25]. Liakou, C.I., Papadakis, M. and Plytas, M., 2025. The challenges for manufacturers under the EU MDR. Int J Eng Technol Res Manag, 9(3).